Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Fluticasone propionate/salmeterol xinafoate: Phase III start

    Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Fluticasone propionate/salmeterol xinafoate (MGR001) Business: Inflammation Molecular target: Adrenergic receptor beta 2 (ADRB2); …

    Published on 10/6/2014
  • INO-3106: Phase I started

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: INO-3106 Business: Cancer Molecular target: NA Description: HPV type 6 immunotherapy Indication: Treat HPV type 6-associated aerodigestive malignances …

    Published on 10/6/2014
  • Lirilumab: Phase II ongoing

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Lirilumab (BMS-986015, IPH2102) Business: Cancer …

    Published on 10/6/2014
  • LymPro Test: Pilot trial completed enrollment

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Memory Dx LLC, Phoenix, Ariz. Product: LymPro Test Business: Diagnostic Molecular target: Not applicable Description: Measure CD69 presentations at …

    Published on 10/6/2014
  • MiStat ELISA: Pilot trial started

    Minomic International Ltd., Macquarie Park, Australia Product: MiStat ELISA Business: Cancer Molecular target: NA Description: Test to detect proprietary biomarker MIL-38 antigen, which is present on prostate cancer …

    Published on 10/6/2014
  • Parsortix cancer cell separation system: Pilot trial started

    Angle plc (LSE:AGL), Guildford, U.K. Product: Parsortix cancer cell separation system Business: Diagnostic Molecular target: NA Description: Microscale device that separates cells on the basis of size and/or surface …

    Published on 10/6/2014
  • Riona ferric citrate: Phase III started

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Panion & BF Biotech Inc. (Taiwan:1760), Taipei, Taiwan Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan …

    Published on 10/6/2014
  • Subcutaneous beloranib: Phase III started

    Zafgen Inc. (NASDAQ:ZFGN), Cambridge, Mass. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Product: Subcutaneous beloranib (ZGN-440, CKD-732) Business: Endocrine/Metabolic Molecular target: …

    Published on 10/6/2014
  • THR-184: Phase II ongoing

    Thrasos Therapeutics Inc., Montreal, Quebec Product: THR-184 Business: Renal Molecular target: Activin receptor-like kinase 2 (ALK2) (ACVR1); Activin receptor-like kinase 3 (ALK3) Description: Small peptide that …

    Published on 10/6/2014
  • Viagenpumatucel-L: Phase II started

    Heat Biologics Inc. (NASDAQ:HTBX), Chapel Hill, N.C. Product: Viagenpumatucel-L (HS-110) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Vaccine comprising lung …

    Published on 10/6/2014
  • Allob: Phase IIa started

    Bone Therapeutics S.A., Gosselies, Belgium Product: Allob Business: Musculoskeletal Molecular target: NA Description: Allogeneic osteoblastic cell therapy Indication: Promote lumbar spine fusion Endpoint: Lumbar fusion …

    Published on 9/29/2014
  • Bertilimumab: Phase II started

    iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), Tarrytown, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab (iCo-008, CAT-…

    Published on 9/29/2014
  • Cysteamine: Phase IIa started

    NovaBiotics Ltd., Aberdeen, U.K. Product: Cysteamine (oral Lynovex) (NM001) Business: Pulmonary Molecular target: NA Description: Oral dual mucoactive-antibacterial Indication: Treat cystic fibrosis (CF) Endpoint: …

    Published on 9/29/2014
  • Flexion Therapeutics pipeline update

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Business: Autoimmune Flexion said FDA placed a clinical hold on a Phase IIb trial of FX006 to treat osteoarthritis (OA) of the knee following an infection in 1 …

    Published on 9/29/2014
  • Fosbretabulin: Phase II started

    OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Fosbretabulin (Combretastatin A4P, Zybrestat)) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated tumor vascular …

    Published on 9/29/2014
  • HaMPCs: Phase 0 started

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Musculoskeletal Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 9/29/2014
  • K-134: Phase II ongoing

    D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Kowa Co. Ltd., Nagoya, Japan Product: K-134 Business: Cardiovascular Molecular target: Phosphodiesterase-3 (PDE-3) Description: Phosphodiesterase-3…

    Published on 9/29/2014
  • Lyxumia lixisenatide: Postmarketing study started

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lyxumia lixisenatide (AVE0010, ZP10) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 …

    Published on 9/29/2014
  • MGN1703: Phase III started

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) …

    Published on 9/29/2014
  • PEGPH20: Phase Ib/II ongoing

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 9/29/2014
  • Rivipansel: Phase III delayed

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 9/29/2014
  • RSV-F vaccine: Phase II started

    Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Product: RSV-F vaccine Business: Infectious Molecular target: NA Description: Respiratory syncytial virus (RSV) vaccine directed against the viral fusion F protein and …

    Published on 9/29/2014
  • TH-302: Phase III ongoing

    Threshold Pharmaceuticals Inc. (NASDAQ:THLD), South San Francisco, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: TH-302 Business: Cancer Molecular target: Not available Description: Hypoxia-activated …

    Published on 9/29/2014
  • TRC105: Phase IIa started

    Tracon Pharmaceuticals Inc., San Diego, Calif. Product: TRC105 Business: Cancer Molecular target: Endoglin (CD105) (ENG) Description: Human chimeric mAb against endoglin (CD105; ENG) Indication: Treat advanced soft …

    Published on 9/29/2014
  • ALKS 3831: Completed Phase II enrollment

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 3831 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Combination of samidorphan, a mu opioid receptor (OPRM1; MOR) antagonist…

    Published on 9/22/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993